secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001558370-24-007475
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroBo Q1 net loss $6.7M; first patient dosed in DA-1726 obesity trial
-----------------------------------------------------------------------

- Net loss of $6.7M ($1.32 per share) vs $2.6M ($0.51) in Q1 2023; R&D spend rose to $4.9M from $0.6M.
- Cash $16.0M as of March 31, 2024, down from $22.4M at year-end 2023; expects runway into Q4 2024.
- First patient dosed in Phase 1 SAD part of DA-1726 for obesity; top-line SAD data expected Q3 2024.
- Phase 2a trial of DA-1241 for MASH fully enrolled in Part 1; Part 2 with sitagliptin enrolling; top-line data expected Q4 2024.
- Appointed Marshall Woodworth as CFO (previously acting); exploring financing alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024007475/0001558370-24-007475-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024007475/nrbo-20240509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007475

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer